Day 2

DAY 2 – TUESDAY 27 FEBRUARY 2018

PLENARY SESSION 2 (PART II) : RARE CANCERS

PLENARY SESSION 3: DEVELOPMENT AND APPROVAL PATHWAY FOR CHANGES IN DOSING REGIMES

PLENARY SESSION 4: PATIENTS’ REPORTED OUTCOMES IN ONCOLOGY PATIENT-CENTERED DRUG DEVELOPMENT: OPPORTUNITIES & CHALLENGES

See the general presentation including:

  • Introduction of Panelists and Topics – Sarah Bobiak (EMD Serono/Merck KGaA, USA)
  • Study Design – Daniel O’Connor (MHRA, UK)
  • Endpoints – Amylou Dueck (Mayo Clinic, USA)
  • Instruments, Measure Validity – Andrew Bottomley (EORTC, BE)
  • Closing remarks – Eva Skovlund (NTNU, NO)

PLENARY SESSION 5: TRANSLATION OF CANCER BIOMARKERS INTO CLINICAL PRACTICE

PLENARY SESSION 6: REPORT FROM CDDF MULTI-STAKEHOLDER WORKSHOPS